Involvement of neuronal TGF-β activated kinase 1 in the development of tolerance to morphine-induced antinociception in rat spinal cord

British Journal of Pharmacology

Volumn 172, Issue 11, 2015, Pages 2892-2904

  Xu, Hao ^a   Xu, Tao ^a   Ma, Xiaqing ^a   Jiang, Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5Z 7 OXOZEAENOL; MITOGEN ACTIVATED PROTEIN KINASE P38; MORPHINE; NEURON SPECIFIC NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; 5-7-OXO-ZEAENOL; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NARCOTIC ANALGESIC AGENT; ZEARALENONE;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MORPHINE TOLERANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RANDALL-SELITTO TEST; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG TOLERANCE; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; NOCICEPTION; SPINAL CORD; SPRAGUE DAWLEY RAT;

ANALGESIA; ANALGESICS, OPIOID; ANIMALS; DRUG TOLERANCE; IMMUNOHISTOCHEMISTRY; INFUSIONS, SPINAL; MALE; MAP KINASE KINASE KINASES; MORPHINE; NOCICEPTION; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; UP-REGULATION; ZEARALENONE;

EID: 84929155045     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13094     Document Type: Article

References (65)

1. Adhikari A, Xu M, Chen ZJ, (2007). Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26: 3214-3226.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Chen Y, Geis C, Sommer C, (2008). Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway. J Neurosci 28: 5836-5845.
4. Cui Y, Chen Y, Zhi JL, Guo RX, Feng JQ, Chen PX, (2006). Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res 1069 (1): 235-243.
5. Cui Y, Liao XX, Liu W, Guo RX, Wu ZZ, Zhao CM, et al. (2008). A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav Immun 22 (1): 114-123.
6. DeLeo JA, Yezierski RP, (2001). The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90: 1-6.
7. Fan XL, Zhang JS, Zhang XQ, Ma L, (2003). Chronic morphine treatment and withdrawal induce up-regulation of c-Jun N-terminal kinase 3 gene expression in rat brain. Neuroscience 122: 997-1002.
8. Ghavimi H, Hassanzadeh K, Maleki-Dizaji N, Azarfardian A, Ghasami S, Zolali E, et al. (2014). Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats. Naunyn Schmiedebergs Arch Pharmacol 387: 811-821.
9. Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, et al. (2013). A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci 16: 1618-1626.
10. de Guglielmo G, Kallupi M, Scuppa G, Stopponi S, Demopulos G, Gaitanaris G, et al. (2014). Analgesic tolerance to morphine is regulated by peroxisome proliferator-activated receptor gamma (PPARgamma). Br J Pharmacol 171: 5407-5416.
11. Guo RX, Zhang M, Liu W, Zhao CM, Cui Y, Wang CH, et al. (2009). NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance. Neurosci Lett 467: 95-99.
12. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, et al. (1999). Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 274: 27161-27167.
13. Horvath RJ, Landry RP, Romero-Sandoval EA, DeLeo JA, (2010). Morphine tolerance attenuates the resolution of postoperative pain and enhances spinal microglial p38 and extracellular receptor kinase phosphorylation. Neuroscience 169: 843-854.
14. Huangfu WC, Omori E, Akira S, Matsumoto K, Ninomiya-Tsuji J, (2006). Osmotic stress activates the TAK1-JNK pathway while blocking TAK1-mediated NF-kappaB activation: TAO2 regulates TAK1 pathways. J Biol Chem 281: 28802-28810.
15. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, et al. (2004). A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 24: 7353-7365.
16. Katsura H, Obata K, Miyoshi K, Kondo T, Yamanaka H, Kobayashi K, et al. (2008). Transforming growth factor-activated kinase 1 induced in spinal astrocytes contributes to mechanical hypersensitivity after nerve injury. Glia 56: 723-733.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
18. King T, Ossipov MH, Vanderah TW, Porreca F, Lai J, (2005). Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 14: 194-205.
19. Klatt AR, Klinger G, Paul-Klausch B, Renno JH, Schmidt J, Malchau G, et al. (2010). TAK1 mediates the collagen-II-dependent induction of the COX-2 gene and PGE2 release in primary human chondrocytes. Connect Tissue Res 51: 452-458.
20. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L, (2011). A comprehensive review of opioid-induced hyperalgesia. Pain Physician 14: 145-161.
21. Liu W, Wang CH, Cui Y, Mo LQ, Zhi JL, Sun SN, et al. (2006). Inhibition of neuronal nitric oxide synthase antagonizes morphine antinociceptive tolerance by decreasing activation of p38 MAPK in the spinal microglia. Neurosci Lett 410: 174-177.
22. Ma W, Zheng WH, Powell K, Jhamandas K, Quirion R, (2001). Chronic morphine exposure increases the phosphorylation of MAP kinases and the transcription factor CREB in dorsal root ganglion neurons: an in vitro and in vivo study. Eur J Neurosci 14: 1091-1104.
23. Mace G, Miaczynska M, Zerial M, Nebreda AR, (2005). Phosphorylation of EEA1 by p38 MAP kinase regulates mu opioid receptor endocytosis. EMBO J 24: 3235-3246.
24. Macey TA, Bobeck EN, Hegarty DM, Aicher SA, Ingram SL, Morgan MM, (2009). Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat. J Pharmacol Exp Ther 331: 412-418.
25. Mao J, Price DD, Mayer DJ, (1995a). Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 61: 353-364.
26. Mao J, Price DD, Mayer DJ, (1995b). Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 62: 259-274.
27. Mayer DJ, Mao J, Holt J, Price DD, (1999). Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci U S A 96: 7731-7736.
28. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
29. Merighi S, Gessi S, Varani K, Fazzi D, Mirandola P, Borea PA, (2012). Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells. Br J Pharmacol 166: 2371-2385.
30. Mizukami J, Takaesu G, Akatsuka H, Sakurai H, Ninomiya-Tsuji J, Matsumoto K, et al. (2002). Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol Cell Biol 22: 992-1000.
31. Moriguchi T, Kuroyanagi N, Yamaguchi K, Gotoh Y, Irie K, Kano T, et al. (1996a). A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem 271: 13675-13679.
32. Moriguchi T, Toyoshima F, Gotoh Y, Iwamatsu A, Irie K, Mori E, et al. (1996b). Purification and identification of a major activator for p38 from osmotically shocked cells. Activation of mitogen-activated protein kinase kinase 6 by osmotic shock, tumor necrosis factor-alpha, and H2O2. J Biol Chem 271: 26981-26988.
33. Narita M, Ioka M, Suzuki M, Suzuki T, (2002). Effect of repeated administration of morphine on the activity of extracellular signal regulated kinase in the mouse brain. Neurosci Lett 324: 97-100.
34. Ndengele MM, Cuzzocrea S, Masini E, Vinci MC, Esposito E, Muscoli C, et al. (2009). Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther 329: 64-75.
35. Neubert M, Ridder DA, Bargiotas P, Akira S, Schwaninger M, (2011). Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ 18: 1521-1530.
36. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K, (1999). The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398: 252-256.
37. Ninomiya-Tsuji J, Kajino T, Ono K, Ohtomo T, Matsumoto M, Shiina M, et al. (2003). A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 278: 18485-18490.
38. Omori E, Matsumoto K, Zhu S, Smart RC, Ninomiya-Tsuji J, (2010). Ablation of TAK1 upregulates reactive oxygen species and selectively kills tumor cells. Cancer Res 70: 8417-8425.
39. Pathak S, Borodkin VS, Albarbarawi O, Campbell DG, Ibrahim A, van Aalten DM, (2012). O-GlcNAcylation of TAB1 modulates TAK1-mediated cytokine release. EMBO J 31: 1394-1404.
40. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
41. Rogers TJ, Peterson PK, (2003). Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 24: 116-121.
42. Saklatvala J, (2004). The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 4: 372-377.
43. Sakurai H, (2012). Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 33: 522-530.
44. Seger R, Krebs EG, (1995). The MAPK signaling cascade. FASEB J 9: 726-735.
45. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, et al. (2005). TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19: 2668-2681.
46. Shirakabe K, Yamaguchi K, Shibuya H, Irie K, Matsuda S, Moriguchi T, et al. (1997). TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J Biol Chem 272: 8141-8144.
47. Silverman N, Zhou R, Erlich RL, Hunter M, Bernstein E, Schneider D, et al. (2003). Immune activation of NF-kappaB and JNK requires Drosophila TAK1. J Biol Chem 278: 48928-48934.
48. Snider RM, Longo KP, Drozda SE, Lowe JA 3rd, Leeman SE, (1991). Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats. Proc Natl Acad Sci U S A 88: 10042-10044.
49. Suzawa M, Takada I, Yanagisawa J, Ohtake F, Ogawa S, Yamauchi T, et al. (2003). Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat Cell Biol 5: 224-230.
50. Taiwo YO, Coderre TJ, Levine JD, (1989). The contribution of training to sensitivity in the nociceptive paw-withdrawal test. Brain Res 487: 148-151.
51. Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K, et al. (2000). TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 5: 649-658.
52. Takeda K, Naguro I, Nishitoh H, Matsuzawa A, Ichijo H, (2011). Apoptosis signaling kinases: from stress response to health outcomes. Antioxid Redox Signal 15: 719-761.
53. Tegeder I, Geisslinger G, (2004). Opioids as modulators of cell death and survival - unraveling mechanisms and revealing new indications. Pharmacol Rev 56: 351-369.
54. Wald D, Commane M, Stark GR, Li X, (2001). IRAK and TAK1 are required for IL-18-mediated signaling. Eur J Immunol 31: 3747-3754.
55. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ, (2001). TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412: 346-351.
56. Wang Z, Ma W, Chabot JG, Quirion R, (2009). Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia. FASEB J 23: 2576-2586.
57. Wang Z, Ma W, Chabot JG, Quirion R, (2010a). Calcitonin gene-related peptide as a regulator of neuronal CaMKII-CREB, microglial p38-NFkappaB and astroglial ERK-Stat1/3 cascades mediating the development of tolerance to morphine-induced analgesia. Pain 151: 194-205.
58. Wang Z, Ma W, Chabot JG, Quirion R, (2010b). Morphological evidence for the involvement of microglial p38 activation in CGRP-associated development of morphine antinociceptive tolerance. Peptides 31: 2179-2184.
59. Watkins LR, Milligan ED, Maier SF, (2001). Spinal cord glia: new players in pain. Pain 93: 201-205.
60. Watkins LR, Hutchinson MR, Johnston IN, Maier SF, (2005). Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 28: 661-669.
61. Xu T, Jiang W, Du D, Xu Y, Hu Q, Shen Q, (2007). Role of spinal metabotropic glutamate receptor subtype 5 in the development of tolerance to morphine-induced antinociception in rat. Neurosci Lett 420: 155-159.
62. Xu T, Jiang W, Du D, Xu Y, Zhou Q, Pan X, et al. (2008). Inhibition of MPEP on the development of morphine antinociceptive tolerance and the biosynthesis of neuronal nitric oxide synthase in rat spinal cord. Neurosci Lett 436: 214-218.
63. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, et al. (1995). Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270: 2008-2011.
64. Zhang D, Hu Y, Sun Q, Zhao J, Cong Z, Liu H, et al. (2013). Inhibition of transforming growth factor beta-activated kinase 1 confers neuroprotection after traumatic brain injury in rats. Neuroscience 238: 209-217.
65. Zhao CM, Guo RX, Hu F, Meng JL, Mo LQ, Chen PX, et al. (2012). Spinal MCP-1 contributes to the development of morphine antinociceptive tolerance in rats. Am J Med Sci 344: 473-479.